Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.42
- Piotroski Score 5.00
- Grade Buy
- Symbol (IOVA)
- Company Iovance Biotherapeutics, Inc.
- Price $10.46
- Changes Percentage (7.12%)
- Change $0.7
- Day Low $9.87
- Day High $10.47
- Year High $18.33
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/29/2024
- Fiscal Year End N/A
- Average Stock Price Target $23.00
- High Stock Price Target $40.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.81
- Trailing P/E Ratio -4.3
- Forward P/E Ratio -4.3
- P/E Growth -4.3
- Net Income $-444,037,000
Income Statement
Quarterly
Annual
Latest News of IOVA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
Iovance Biotherapeutics (NASDAQ: IOVA) is a promising biotech stock due to its unique cell therapy for melanoma, Amtagvi. However, profitability may be a long-term goal, and the company faces challeng...
By Yahoo! Finance | 2 weeks ago -
Iovance Biotherapeutics Shows Market Leadership With Jump To 92 RS Rating
IBD's RS Rating identifies market leaders based on their price performance compared to the market. Stocks with an RS Rating above 80 in the early stages of their moves tend to perform well....
By Investor's Business Daily | 2 weeks ago -
Iovance Biotherapeutics, Inc. (IOVA): Short Seller Sentiment is Bearish on This Cancer Stock
Insider Monkey compiled a list of the 10 worst cancer stocks according to short sellers, focusing on Iovance Biotherapeutics, Inc. Despite being heavily shorted, the company showed optimistic Q2 earni...
By Yahoo! Finance | 2 weeks ago
